Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities (2010 - 2026)

Biocryst Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at -$268.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 1091.5% year-over-year to -$268.6 million; the trailing twelve-month figure through Mar 2026 stood at -$309.4 million (down 707.55% YoY), and the FY2025 full-year result was -$13.7 million, down 126.04% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$268.6 million, down from -$83.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $77.2 million in Q4 2022, with the low at -$268.6 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$28.8 million across 5 years, with a median of -$2.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 2263.37% — and 2025, when it soared 1289.34%.
• Biocryst Pharmaceuticals' Cash from Investing Activities stood at $77.2 million in 2022, then sank by 136.87% to -$28.5 million in 2023, then jumped by 162.5% to $17.8 million in 2024, then plunged by 569.11% to -$83.5 million in 2025, then sank by 221.78% to -$268.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$268.6 million (Q1 2026), -$83.5 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.